DAPTOMYCIN

Search structure
Trade Names:
Synonyms:
Status: Approved (2003)
Entry Type: Small molecule
Molecule Category: UNKNOWN
ATC: J01XX09
UNII: NWQ5N31VKK

Structure
InChI Key DOAKLVKFURWEDJ-RWDRXURGSA-N
Smile CCCCCCCCCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]1C(=O)NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@@H]([C@H](C)CC(=O)O)C(=O)N[C@@H](CC(=O)c2ccccc2N)C(=O)O[C@@H]1C
InChI
InChI=1S/C72H101N17O26/c1-5-6-7-8-9-10-11-22-53(93)81-44(25-38-31-76-42-20-15-13-17-39(38)42)66(108)84-45(27-52(75)92)67(109)86-48(30-59(102)103)68(110)89-61-37(4)115-72(114)49(26-51(91)40-18-12-14-19-41(40)74)87-71(113)60(35(2)24-56(96)97)88-69(111)50(34-90)82-55(95)32-77-63(105)46(28-57(98)99)83-62(104)36(3)79-65(107)47(29-58(100)101)85-64(106)43(21-16-23-73)80-54(94)33-78-70(61)112/h12-15,17-20,31,35-37,43-50,60-61,76,90H,5-11,16,21-30,32-34,73-74H2,1-4H3,(H2,75,92)(H,77,105)(H,78,112)(H,79,107)(H,80,94)(H,81,93)(H,82,95)(H,83,104)(H,84,108)(H,85,106)(H,86,109)(H,87,113)(H,88,111)(H,89,110)(H,96,97)(H,98,99)(H,100,101)(H,102,103)/t35-,36-,37-,43+,44+,45+,46+,47+,48+,49+,50-,60+,61+/m1/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C72H101N17O26
Molecular Weight 1620.69
AlogP None
Hydrogen Bond Acceptor None
Hydrogen Bond Donor None
Number of Rotational Bond None
Polar Surface Area None
Molecular species None
Aromatic Rings None
Heavy Atoms None

Pharmacology

Action Mechanism of Action Reference
INHIBITOR Cell membrane inhibitor DailyMed Wikipedia
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Transporter Primary active transporter ATP-binding cassette ABCC subfamily
- 29100 - - -

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Endocarditis 4 D004696 ClinicalTrials
Endocarditis 4 D004696 ClinicalTrials
Staphylococcal Infections 3 D013203 ClinicalTrials
Pneumonia, Bacterial 3 D018410 ClinicalTrials
Osteomyelitis 3 D010019 ClinicalTrials
Skin Diseases 3 D012871 ClinicalTrials
Diabetic Foot 3 D017719 ClinicalTrials
Bacteremia 3 D016470 ClinicalTrials
Renal Insufficiency 3 D051437 ClinicalTrials
Endocarditis, Bacterial 3 D004697 ClinicalTrials
Gram-Positive Bacterial Infections 3 D016908 ClinicalTrials
Meningitis, Pneumococcal 2 D008586 ClinicalTrials
Sepsis 1 D018805 ClinicalTrials
Meningitis 1 D008581 ClinicalTrials
Renal Insufficiency, Chronic 1 D051436 ClinicalTrials

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
General disorders and administration site conditions
14.65
Infections and infestations
11.33
Respiratory, thoracic and mediastinal disorders
10.86
Investigations
9.98
Injury, poisoning and procedural complications
9.63
Blood and lymphatic system disorders
5.62
Musculoskeletal and connective tissue disorders
4.75
Cardiac disorders
4.65
Vascular disorders
4.6
Nervous system disorders
4.02
Skin and subcutaneous tissue disorders
3.76
Immune system disorders
3.03
Renal and urinary disorders
3.01
Metabolism and nutrition disorders
2.45
Gastrointestinal disorders
2.17

Cross References

Resources Reference
CAS NUMBER 103060-53-3
ChEBI 600103
ChEMBL CHEMBL387675
EPA CompTox DTXSID1041009
FDA SRS NWQ5N31VKK
Guide to Pharmacology 10904
PubChem 21585658
SureChEMBL SCHEMBL28102
CONTENTS